SCHOOL OF MEDICINE  |  PITT HOME  |  FIND PEOPLE  |  FIND A DOCTOR AT UPMC

Department of Medicine

Department of Medicine

 Division of Infectious Diseases

[Return To Index page]
photo Yohei Doi, MD, PhD

Director, Center for Innovative Antimicrobial Therapy

Email: DoiY@dom.pitt.edu

Phone: 412-648-9445

Contact
Office: Scaife Hall, Suite 829
3550 Terrace Street
Pittsburgh, PA 15213
 
Phone: 412-648-9445
Fax: 412-648-8521
E-mail: DoiY@dom.pitt.edu
Administrative Assistant:
Tanya Gonzales
Address: S869,Scaife Hall
3550 Terrace Street
Pittsburgh, PA 15261
Email: tal67@pitt.edu
Phone: 412-648-8510
Fax: 412-648-8455
Education and Training
Education
Bachelor of Medicine, Nagoya University School of Medicine, 1998
Doctor of Medicine, Nagoya University School of Medicine, 2004
Training
Medicine, Anjo Kosei Hospital, 1998
Medicine, St. Luke's-Roosevelt Hospital Center, 2003
Infectious Diseases, University of Pittsburgh Medical Center, 2005
Research Interest
The mission of Dr. Doi's laboratory is to identify and investigate antimicrobial resistance of clinical concern among gram-negative bacterial pathogens. The areas of research include the genetic and molecular basis of emerging antimicrobial resistance mechanisms; the rapid diagnosis of resistance using phenotypic, genetic, and lipidomic approaches; and inhibitor-based drug discovery. Current efforts are focused on colistin resistance in Acinetobacter baumannii, a problematic healthcare-associated pathogen, and fosfomycin resistance in Escherichia coli, the predominant cause of urinary tract infection in both healthcare and community settings. The latter work has expanded into drug discovery effort aimed at reversing resistance using an inhibitor-based approach.
Clinical Interest
Dr. Doi rounds on the general infectious diseases consult services as an attending physician and provides teaching on antimicrobial resistance mechanisms.
Educational Interest
Dr. Doi is involved in the Medical Microbiology course for the first-year medical students.
Publications
For my complete bibliography, Click Here.
Selected Publications:
Doi Y, Paterson DL, Egea P, Pascual A, López-Cerero L, Navarro MD, Adams-Haduch JM, Qureshi ZA, Sidjabat HE. Extended-spectrum and CMY-type beta-lactamase-producing Escherichia coli in clinical samples and retail meat from Pittsburgh, US, and Seville, Spain. Clin Microbiol Infect. 2009.
Doi Y, Paterson DL, Adams-Haduch JM, Sidjabat HE, O'Keefe A, Endimiani A, Bonomo RA. Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 beta-lactamase. Antimicrob Agents Chemother. 2009; 53: 3159-61.
Sidjabat HE, Paterson DL, Qureshi ZA, Adams-Haduch JM, O'Keefe A, Pascual A, Rodríguez-Baño J, Doi Y. Clinical features and molecular epidemiology of CMY-type beta-lactamase-producing Escherichia coli. Clin Infect Dis. 2009; 48: 739-44.
Doi Y, Potoski BA, Adams-Haduch JM, Sidjabat HE, Pasculle AW, Paterson DL. Simple disk-based method for detection of KPC-type beta-lactamase using a boronic acid compound. J Clin Microbiol. 2008; 46: 4083-6.
Adams-Haduch JM, Paterson DL, Sidjabat HE, Pasculle AW, Potoski BA, Muto CA, Harrison LH, Doi Y. Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania. Antimicrob Agents Chemother. 2008; 52: 3837-43.
Sponsored Research/Activities
Title: Mechanisms and Implications of Fosfomycin Resistance in Escherichia Coli
Role: Principal Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: R21 AI123747
Start Year: 2016
End Year: 2018
Title: Gram Negative ARLG Steering Committee Chair
Role: Principal Investigator
Funding Agency: Duke University/National Institute of Allergy & Infectious Diseases
Grant Number: UM1 AI104681
Start Year: 2015
End Year: 2017
Title: Enhancing Neutrophil Responses to Counter MDR Gram Negative Bacterial Pneumonia
Role: Principal Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: R21 AI119042
Start Year: 2015
End Year: 2017
Title: Colistin-Resistant Acinetobacter baumannii
Role: Principal Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: R01 AI104895
Start Year: 2014
End Year: 2019
Title: Antibacterial Resistance Leadership Group (ARLG) CRACKLE Study
Role: Principal Investigator
Funding Agency: University of North Carolina/National Institute of Allergy & Infectious Diseases
Grant Number: UM1 AI104681
Start Year: 2014
End Year: 2015
Title: Marker Predicting Response to Therapy for KPC-producing Klebsiella Pneumoniae
Role: Principal Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: R21 AI107302
Start Year: 2013
End Year: 2016
Title: Optimizing Detection of MRSA Carriage
Role: Principal Investigator
Funding Agency: Agency for Healthcare Research and Quality
Grant Number: R03 HS021521
Start Year: 2012
End Year: 2014
Title: Multidrug Resistant Acinetobacter Baumannii
Role: Principal Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: K22 AI080584
Start Year: 2009
End Year: 2013
Title: Consortium on Resistance Against Carbapenems in Klebsiella pneumoniae and Other Enterobacteriaceae (CRACKLE): a Prospective, Observational Cohort Study
Role: Co-Investigator
Funding Agency: Duke University
Grant Number: UM1 AI104681
Start Year: 2016
End Year: 2019
Title: Procalcitionin Antibiotic Consensus Trial (ProACT)
Role: Co-Investigator
Funding Agency: National Institute of General Medical Science
Grant Number: R01 GM101197
Start Year: 2013
End Year: 2018
Notable Achievements
Associate Editor
Antimicrobial Agents and Chemotherapy Editorial Board Member
Journal of Clinical Microbiology
Diagnostic Microbiology and Infectious Disease
Honoree, University of Pittsburgh Honors Convocation, 2015